slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 93,931-93,960
Pages 3,685
Rows per page 30
Component
93,931-93,960 of 110,539
05
Includes a dual-axis line chart for historical trends and a table for future projections.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
06
The chart compares 2023 quarterly volumes against Q1 2024 volume.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
03
The slide uses a 2x2 grid layout to present key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Golden Circle1 hit
06
The slide uses a timeline visual to connect high-level goals with specific 2024 milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left-hand sidebar for board/advisors and a right-hand grid for the leadership team.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
11
The chart uses a bar-horizontal format to compare sales figures for specific drugs (Alectinib, Crizotinib) against a group of 'Other' TKIs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market Size1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Includes a table detailing patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a waterfall plot and a summary table of best responses.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data from ARROS-1 Phase 1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide highlights the Recommended Phase 2 Dose (RP2D) selection based on safety and PK data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
41
The slide uses a timeline framework to connect current clinical status to the 'OnTarget 2026' mission.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Oatly | Results Presentation Deck | 43 slidesOatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit
13
The chart shows a steady increase in volume across New European and International markets, with a 29% growth callout.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
29
The slide uses a waterfall bridge to reconcile cash flow, highlighting specific operational impacts like plant exit costs and working capital phasing.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
30
The slide uses a simple list-based layout to communicate key financial targets.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
04
Includes a non-GAAP disclaimer at the bottom.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations 1 hit
05
Includes non-GAAP disclosure note at the bottom.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · SolutionLoop · Logic Chain1 hit
06
Includes non-GAAP financial measure disclosure.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · SolutionLoop · Logic Chain1 hit
09
The chart displays steady growth in loans held for investment (HFI) in major metropolitan markets.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The slide uses a pie chart to visualize credit tiers and a bulleted list for portfolio metrics.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · Financials1 hit
14
The chart includes both absolute dollar values and percentage of revenue metrics.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · Financials1 hit
16
The chart displays quarterly financial performance metrics for South Plains Financial, Inc.South Plains Financial | Investor Presentation Deck | 27 slides · South Plains Financial
Pitch deck Investor relations Beat · Financials1 hit
13
Includes a timeline of 2023 milestones and visual evidence of patents and research partnerships.Yatsen | Results Presentation Deck | 20 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Satisfaction1 hit